Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Neurologia (Engl Ed) ; 38(3): 159-172, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37059571

ABSTRACT

The prevalence of multiple sclerosis (MS) in Asian countries is thought to be lower than in Western countries, with Asian populations presenting 80% less risk of MS than white populations. Incidence and prevalence rates in Asian countries are therefore not well defined and their association with rates in neighboring countries, as well as with ethnic, environmental, and socioeconomic factors, are not well understood. We performed a comprehensive literature review of epidemiological data from China and neighbouring countries to study the frequency of the disease, focusing on prevalence, and the progression over time and the influence of sex-related, environmental, dietary, and sociocultural factors. Prevalence rates in China range between 0.88 cases/100,000 population in 1986 and 5.2 cases/100,000 population in 2013, with a non-significant upwards trend (p = .08). The increase observed in Japan, where figures ranged between 8.1 and 18.6 cases/100,000 population was highly significant (p < .001). Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015 (r2 = 0.79, p < .0001). In conclusion, the prevalence of MS in China appears to have risen in recent years, although Asian populations (including Chinese and Japanese populations, among others) appear to present less risk than other populations. Within Asia, geographical latitude appears not to be a determining factor for developing MS.


Subject(s)
Multiple Sclerosis , Humans , Multiple Sclerosis/epidemiology , Incidence , Prevalence , Asia/epidemiology , China/epidemiology
2.
Neurología (Barc., Ed. impr.) ; 38(3): 159-172, abril 2023. mapas, tab, graf
Article in Spanish | IBECS | ID: ibc-218078

ABSTRACT

La prevalencia de la esclerosis múltiple (EM) en los países asiáticos se considera que es más baja que en los países occidentales, las poblaciones asiáticas tienen un 80% menos de riesgo de EM que las caucásicas. No se conocen bien las cifras de incidencia, prevalencia y su relación con otros países de su entorno y su relación con factores étnicos, ambientales y socioeconómicos.Hemos realizado una revisión bibliográfica exhaustiva de los datos epidemiológicos existentes en China y países limítrofes, para estudiar la frecuencia de la enfermedad, centrándonos en la prevalencia, sus cambios evolutivos a lo largo del tiempo y su relación con factores de género, ambientales, alimenticios y socioculturales.La prevalencia en China oscila en cifras que van desde 0,88 en 1986 a 5,2 en 2013 por 100.000 habitantes con una tendencia a aumentar que no es estadísticamente significativa (p = 0,08), mientras que en Japón este incremento es muy significativo, con cifras que oscilan entre 8,1 y 18,6 (p < 0,001). La prevalencia en los países donde predomina la raza caucásica son mucho más elevadas y aumentan con el tiempo, llegando a 115 por 100.000 habitantes en 2015 (r2 = 0,79, p = 0,0001).En conclusión, la prevalencia de la EM en China parece está aumentando en los últimos años, aunque la raza amarilla (chinos y japoneses, entre otros) tienen menor riesgo de padecerla que el resto de las poblaciones. La latitud no parece ser un factor muy determinante en Asia para presentar un mayor riesgo de padecer EM. (AU)


The prevalence of multiple sclerosis (MS) in Asian countries is thought to be lower than in Western countries, with Asian populations presenting 80% less risk of MS than white populations. Incidence and prevalence rates in Asian countries are therefore not well defined and their association with rates in neighboring countries, as well as with ethnic, environmental, and socioeconomic factors, are not well understood.We performed a comprehensive literature review of epidemiological data from China and neighbouring countries to study the frequency of the disease, focusing on prevalence, and the progression over time and the influence of sex-related, environmental, dietary, and sociocultural factors.Prevalence rates in China range between 0.88 cases/100,000 population in 1986 and 5.2 cases/100,000 population in 2013, with a non-significant upwards trend (p = .08). The increase observed in Japan, where figures ranged between 8.1 and 18.6 cases/100,000 population was highly significant (p < .001). Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015 (r2 = 0.79, p < .0001).In conclusion, the prevalence of MS in China appears to have risen in recent years, although Asian populations (including Chinese and Japanese populations, among others) appear to present less risk than other populations. Within Asia, geographical latitude appears not to be a determining factor for developing MS. (AU)


Subject(s)
Humans , Multiple Sclerosis , Prevalence , Epidemiology , China , Asia
3.
Neurologia (Engl Ed) ; 2020 Oct 14.
Article in English, Spanish | MEDLINE | ID: mdl-33069449

ABSTRACT

The prevalence of multiple sclerosis (MS) in Asian countries is thought to be lower than in Western countries, with Asian populations presenting 80% less risk of MS than white populations. Incidence and prevalence rates in Asian countries are therefore not well defined and their association with rates in neighboring countries, as well as with ethnic, environmental, and socioeconomic factors, are not well understood. We performed a comprehensive literature review of epidemiological data from China and neighbouring countries to study the frequency of the disease, focusing on prevalence, and the progression over time and the influence of sex-related, environmental, dietary, and sociocultural factors. Prevalence rates in China range between 0.88 cases/100,000 population in 1986 and 5.2 cases/100,000 population in 2013, with a non-significant upwards trend (p = .08). The increase observed in Japan, where figures ranged between 8.1 and 18.6 cases/100,000 population was highly significant (p < .001). Prevalence rates in countries with predominantly white populations are considerably higher and have increased over time, reaching 115 cases/100,000 population in 2015 (r2 = 0.79, p < .0001). In conclusion, the prevalence of MS in China appears to have risen in recent years, although Asian populations (including Chinese and Japanese populations, among others) appear to present less risk than other populations. Within Asia, geographical latitude appears not to be a determining factor for developing MS.

4.
Immun Ageing ; 16: 14, 2019.
Article in English | MEDLINE | ID: mdl-31312227

ABSTRACT

BACKGROUND: Seasonal influenza virus infection is a significant cause of morbimortality in the elderly. However, there is poor vaccine efficacy in this population due to immunosenescence. We aimed to explore several homeostatic parameters in the elderly that could impact influenza vaccine responsiveness. METHODS: Subjects (> 60 years old) who were vaccinated against influenza virus were included, and the vaccine response was measured by a haemagglutination inhibition (HAI) test. At baseline, peripheral CD4 and CD8 T-cells were phenotypically characterized. Thymic function and the levels of different inflammation-related biomarkers, including Lipopolysaccharide Binding Protein (LBP) and anti-cytomegalovirus (CMV) IgG antibodies, were also measured. RESULTS: Influenza vaccine non-responders showed a tendency of higher frequency of regulatory T-cells (Tregs) before vaccination than responders (1.49 [1.08-1.85] vs. 1.12 [0.94-1.63], respectively, p = 0.061), as well as higher expression of the proliferation marker Ki67 in Tregs and different CD4 and CD8 T-cell maturational subsets. The levels of inflammation-related biomarkers correlated with the frequencies of different proliferating T-cell subsets and with thymic function (e.g., thymic function with D-dimers, r = - 0.442, p = 0.001). CONCLUSIONS: Age-related homeostatic dysregulation involving the proliferation of CD4 and CD8 T-cell subsets, including Tregs, was related to a limited responsiveness to influenza vaccination and a higher inflammatory status in a cohort of elderly people.

5.
Med. intensiva (Madr., Ed. impr.) ; 41(8): 468-474, nov. 2017. graf
Article in English | IBECS | ID: ibc-168424

ABSTRACT

Objective: Cerebral vasospasm, one of the main complications of subarachnoid hemorrhage (SAH), is characterized by arterial constriction and mainly occurs from day 4 until the second week after the event. Urotensin-II (U-II) has been described as the most potent vasoconstrictor peptide in mammals. An analysis is made of the serum U-II concentrations and mRNA expression levels of U-II, urotensin related peptide (URP) and urotensin receptor (UT) genes in an experimental murine model of SAH. Design: An experimental study was carried out. Setting: Experimental operating room of the Biomedicine Institute of Seville (IBiS), Virgen del Rocío University Hospital (Seville, Spain). Participants: 96 Wistar rats: 74 SAH and 22 sham intervention animals. Interventions: Day 1: blood sampling, followed by the percutaneous injection of 100μl saline (sham) or blood (SAH) into the subarachnoid space. Day 5: blood sampling, followed by sacrifice of the animals. Main variables of interest: Weight, early mortality, serum U-II levels, mRNA values for U-II, URP and UT. Results: Serum U-II levels increased in the SAH group from day 1 (0.62pg/mL [IQR 0.36-1.08]) today 5 (0.74pg/mL [IQR 0.39-1.43]) (p<0.05), though not in the sham group (0.56pg/mL [IQR 0.06-0.83] day 1; 0.37pg/mL [IQR 0.23-0.62] day 5; p=0.959). Between-group differences were found on day 5 (p<0.05). The ROC analysis showed that the day 5 serum U-II levels (AUC=0.691), URP mRNA (AUC=0.706) and UT mRNA (AUC=0.713) could discriminate between sham and SAH rats. The normal serum U-II concentration range in rats was 0.56pg/mL (IQR 0.06-0.83). Conclusion: The urotensinergic system is upregulated on day 5 in an experimental model of SAH (AU)


Objetivo: El vasoespasmo cerebral, una de las principales complicaciones secundarias a hemorragia subaracnoidea (HSA), se caracteriza por una constricción arterial que tiene lugar principalmente entre el día 4 y la segunda semana. La urotensina-II (U-II) ha sido definida como el péptido con mayor capacidad vasoconstrictora en mamíferos. Quisimos analizar los niveles séricos de U-II, así como los niveles de expresión de los genes de U-II, péptido relacionado con urotensina y receptor de urotensina, en un modelo murino experimental de HSA. Diseño: Estudio experimental. Ámbito: Quirófano experimental del Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío. Participantes: Noventa y seis ratas Wistar: 74 con inyección percutánea de sangre (HSA), 22 con inyección percutánea de 100μL de salino (Sham). Intervenciones: Día 1: extracción de muestras de sangre. Posteriormente, inyección percutánea de 100μL de salino (Sham) o de sangre (HSA) en el espacio subaracnoideo. Día 5: extracción de muestras de sangre y sacrificio del animal. Principales variables de interés: Peso, mortalidad precoz, niveles séricos de U-II, valores de ARNm de U-II, péptido relacionado con urotensina y receptor de urotensina. Resultados: Observamos un incremento en los niveles de U-II sérica en el grupo HSA desde el día 1 (0,62pg/mL [RI 0,36-1,08]) al día 5 (0,74pg/mL [RI 0,39-1,43]) (p<0,05); pero no observamos tal diferencia en el grupo Sham (0,56pg/mL [RI 0,06-0,83] día 1; 0,37pg/mL [RI 0,23-0,62] día 5) (p=0,959). Se encontraron diferencias en los niveles de U-II entre ambos grupos al quinto día (p<0,05). El análisis de curvas ROC demostró que la U-II sérica al quinto día (AUC=0,691), ARNm de péptido relacionado con urotensina (AUC=0,706) y ARNm de receptor de urotensina (AUC=0,713) podían discriminar entre ratas Sham y HSA. Además, definimos un rango de normalidad para los niveles de U-II séricos en ratas: 0,56pg/mL (RI 0,06-0,83). Conclusión: Este estudio demuestra por primera vez que el sistema urotensinérgico ve incrementada su expresión en el quinto día en un modelo de HSA (AU)


Subject(s)
Animals , Rats , Subarachnoid Hemorrhage/blood , Subarachnoid Hemorrhage/diagnosis , Disease Models, Animal , Biomarkers/analysis , Subarachnoid Hemorrhage/veterinary , Rats, Wistar , Vasospasm, Intracranial/diagnosis , Vasospasm, Intracranial/veterinary , Urotensins/blood
6.
Med Intensiva ; 41(8): 468-474, 2017 Nov.
Article in English, Spanish | MEDLINE | ID: mdl-28081921

ABSTRACT

OBJECTIVE: Cerebral vasospasm, one of the main complications of subarachnoid hemorrhage (SAH), is characterized by arterial constriction and mainly occurs from day 4 until the second week after the event. Urotensin-II (U-II) has been described as the most potent vasoconstrictor peptide in mammals. An analysis is made of the serum U-II concentrations and mRNA expression levels of U-II, urotensin related peptide (URP) and urotensin receptor (UT) genes in an experimental murine model of SAH. DESIGN: An experimental study was carried out. SETTING: Experimental operating room of the Biomedicine Institute of Seville (IBiS), Virgen del Rocío University Hospital (Seville, Spain). PARTICIPANTS: 96 Wistar rats: 74 SAH and 22 sham intervention animals. INTERVENTIONS: Day 1: blood sampling, followed by the percutaneous injection of 100µl saline (sham) or blood (SAH) into the subarachnoid space. Day 5: blood sampling, followed by sacrifice of the animals. MAIN VARIABLES OF INTEREST: Weight, early mortality, serum U-II levels, mRNA values for U-II, URP and UT. RESULTS: Serum U-II levels increased in the SAH group from day 1 (0.62pg/mL [IQR 0.36-1.08]) to day 5 (0.74pg/mL [IQR 0.39-1.43]) (p<0.05), though not in the sham group (0.56pg/mL [IQR 0.06-0.83] day 1; 0.37pg/mL [IQR 0.23-0.62] day 5; p=0.959). Between-group differences were found on day 5 (p<0.05). The ROC analysis showed that the day 5 serum U-II levels (AUC=0.691), URP mRNA (AUC=0.706) and UT mRNA (AUC=0.713) could discriminate between sham and SAH rats. The normal serum U-II concentration range in rats was 0.56pg/mL (IQR 0.06-0.83). CONCLUSION: The urotensinergic system is upregulated on day 5 in an experimental model of SAH.


Subject(s)
Gene Expression Regulation , Peptide Hormones/blood , RNA, Messenger/blood , Receptors, G-Protein-Coupled/blood , Subarachnoid Hemorrhage/genetics , Urotensins/genetics , Vasospasm, Intracranial/genetics , Animals , Biomarkers , Disease Models, Animal , Peptide Hormones/biosynthesis , Peptide Hormones/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , ROC Curve , Rats , Rats, Wistar , Real-Time Polymerase Chain Reaction , Receptors, G-Protein-Coupled/biosynthesis , Receptors, G-Protein-Coupled/genetics , Sensitivity and Specificity , Subarachnoid Hemorrhage/complications , Urotensins/biosynthesis , Urotensins/blood , Vasoconstriction/genetics , Vasospasm, Intracranial/etiology
7.
J Physiol Pharmacol ; 66(5): 643-52, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26579570

ABSTRACT

Melatonin is an indoleamine with multiple functions in both plant and animal species. In addition to data in literature describing many other important roles for melatonin, such as antioxidant, circadian rhythm controlling, anti-aging, antiproliferative or immunomodulatory activities, our group recently reported that thyroid C-cells synthesize melatonin and suggested a paracrine role for this molecule in the regulation of thyroid activity. To discern the role played by melatonin at thyroid level and its involvement in the hypothalamic-pituitary-thyroid axis, in the present study we have analyzed the effect of thyrotropin in the regulation of the enzymatic machinery for melatonin biosynthesis in C cells as well as the effect of melatonin in the regulation of thyroid hormone biosynthesis in thyrocytes. Our results show that the key enzymes for melatonin biosynthesis (AANAT and ASMT) are regulated by thyroid-stimulating hormone. Furthermore, exogenous melatonin increases thyroglobulin expression at mRNA and protein levels on cultured thyrocytes and this effect is not strictly mediated by the upregulation of TTF1 or, noteworthy, PAX8 transcription factors. The present data show that thyroid C-cells synthesize melatonin under thyroid-stimulating hormone control and, consistently with previous data, support the hypothesis of a paracrine role for C-cell-synthesised melatonin within the thyroid gland. Additionally, in the present study we show evidence for the involvement of melatonin in thyroid function by directly-regulating thyroglobulin gene expression in follicular cells.


Subject(s)
Melatonin/metabolism , Thyroglobulin/metabolism , Thyroid Gland/physiology , Thyrotropin/metabolism , Animals , Gene Expression Regulation/genetics , Male , Melatonin/biosynthesis , RNA, Messenger/metabolism , Rats , Rats, Wistar , Thyroglobulin/genetics , Thyroid Gland/cytology , Thyroid Hormones/biosynthesis , Thyroid Hormones/metabolism
8.
J Antimicrob Chemother ; 69(11): 3041-6, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25011654

ABSTRACT

BACKGROUND: Chronic and systemic inflammatory alterations occur in HIV-infected patients and elderly uninfected subjects and in both scenarios these alterations are associated with the development of chronic morbidities and mortality. However, whether the levels of inflammatory alterations in untreated HIV-infected patients and elderly individuals are similar is unknown. Moreover, whether long-term antiretroviral therapy normalizes inflammatory alterations compared with HIV-uninfected persons of different age is not known. METHODS: We analysed soluble inflammatory levels [high-sensitivity C-reactive protein, interferon (IFN)-γ, tumour necrosis factor (TNF)-α, interleukin (IL)-1ß, IL-6, IL-8 and IL-17] in a cohort of viraemic HIV-infected patients compared with (i) age-matched, (ii) elderly and (iii) non-survivor elderly, uninfected healthy controls. We longitudinally analysed the effect of long-term 48 and 96 week suppressive combined antiretroviral therapy (cART) on the soluble inflammatory levels compared with those found in control subjects. RESULTS: Baseline IL-6 and IL-8 levels were at similar or lower concentrations in untreated patients compared with healthy elderly individuals. However, TNF-α and IFN-γ levels broadly exceeded those found in survivors and non-survivor elderly individuals. Long-term suppressive cART normalized most of the inflammatory markers, with the exception of TNF-α levels, which persisted as high as those in elderly non-survivor controls. CONCLUSIONS: Chronic inflammatory alterations associated with HIV infection are maintained at a different level from those of ageing. The persistent alteration of TNF-α levels in HIV-infected patients might cause tissue damage and have implications for developing non-AIDS-defining illnesses, even when HIV replication is long-term controlled by cART.


Subject(s)
Anti-Retroviral Agents/administration & dosage , HIV Infections/blood , HIV Infections/drug therapy , Tumor Necrosis Factor-alpha/blood , Aged , Aged, 80 and over , Cohort Studies , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Retrospective Studies , Time Factors
9.
Curr Pharm Des ; 20(30): 4841-53, 2014.
Article in English | MEDLINE | ID: mdl-24251676

ABSTRACT

The role of melatonin in glucose homeostasis is an active area of investigation. There is a growing body of evidence suggesting a link between disturbances in melatonin production and impaired insulin, glucose, lipid metabolism, and antioxidant capacity. Furthermore, melatonin has been found to influence insulin secretion both in vivo and in vitro, and night-time melatonin levels are related to night-time insulin concentrations in patients with diabetes. In several recent studies, a single nucleotide polymorphism of the human melatonin receptor 1B has been described as being causally linked to an increased risk of developing type 2 diabetes. Taken together, these data suggest that endogenous as well as exogenous melatonin may play a role in diabetes and associated metabolic disturbances not only by regulating insulin secretion but also by providing protection against reactive oxygen species, considering pancreatic ß-cells are particularly susceptible to oxidative stress because they possess only low-antioxidative capacity.


Subject(s)
Glucose/metabolism , Melatonin/physiology , Diabetes Mellitus, Type 2/genetics , Glucagon/metabolism , Homeostasis/physiology , Humans , Insulin/metabolism , Insulin Secretion , Polymorphism, Genetic , Receptors, Melatonin/genetics
10.
Clin Lab ; 57(11-12): 1011-4, 2011.
Article in English | MEDLINE | ID: mdl-22239035

ABSTRACT

BACKGROUND: A study to analyse tumor markers (CEA, CA125, CA15.3, CA19.9, CYFRA 21-1, and NSE) for metastasis detection in lung cancer patients. METHODS: Serum tumor markers from 73 lung cancer patients were measured before they were diagnosed. After lung cancer diagnosis, tumor markers were analyzed for the detection of distant metastases. RESULTS: In NSCLC patients CYFRA 21-1 and NSE showed differences between stage IV and any of the other stages, p < 0.05. The accuracy for metastasis detection was AUC = 81.5 % for CYFRA 21-1 and AUC = 78.6 % for < 0.05) were independent predictors for metastasis presence. No tumor marker showed significant differences according to stages in SCLC patients. CONCLUSIONS: CYFRA 21-1 could be used as a screening tool for metastasis detection in lung cancer patients without symptoms of metastasis as well as CYFRA 21-1 and NSE in NSCLC patients.


Subject(s)
Antigens, Neoplasm/blood , Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Small Cell/secondary , Keratin-19/blood , Lung Neoplasms/blood , CA-125 Antigen/blood , CA-19-9 Antigen/blood , Carcinoembryonic Antigen/analysis , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Small Cell/blood , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Membrane Proteins/blood , Mucin-1/blood , Neoplasm Proteins/blood , Neoplasm Staging , Phosphopyruvate Hydratase/blood , ROC Curve , Sensitivity and Specificity
11.
Cell Mol Life Sci ; 66(3): 516-25, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19099187

ABSTRACT

Human lymphocyte melatonin, through membrane and nuclear receptors binding, acts as an activator in IL-2 production. Antagonism of membrane melatonin receptors using luzindole exacerbates the drop of the IL-2 production induced by PGE(2) in peripheral blood mononuclear and Jurkat cells. This paper studies the melatonin membrane and nuclear receptors interplay in PGE(2)-diminished IL-2 production. The decrease in IL-2 production after PGE(2) and/or luzindole administration correlated with downregulation in the nuclear receptor RORalpha. We also highlighted a role of cAMP in the pathway, because forskolin mimicked the effects of luzindole and/or PGE(2) in the RORalpha expression. Finally, a significant RORalpha downregulation was observed in T cells permanently transfected with inducible MT(1) antisense. In conclusion, we show a novel connection between melatonin membrane receptor signalling and RORalpha expression, opening a new way to understand melatonin regulation in lymphocyte physiology.


Subject(s)
Cell Membrane/metabolism , Cell Nucleus/metabolism , Interleukin-2/metabolism , Lymphocytes/metabolism , Receptors, Melatonin/metabolism , Adult , Animals , Cyclic AMP/metabolism , Dinoprostone/metabolism , Humans , Jurkat Cells , Lymphocytes/cytology , Melatonin/metabolism , Middle Aged , Nuclear Receptor Subfamily 1, Group F, Member 1 , Receptors, Cytoplasmic and Nuclear/metabolism , Trans-Activators/metabolism , Tryptamines/metabolism
12.
Cell Mol Life Sci ; 64(6): 781-90, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17334663

ABSTRACT

Melatonin is an indoleamine widely distributed in the evolution that shows a great functional versatility, playing an important role as a transmitter of photoperiodic information and exhibiting antioxidant, oncostatic, anti-aging and immunomodulatory properties. In vertebrates, this molecule is produced by the pineal gland and other extrapineal sites. The present study was carried out to investigate the presence of melatonin in thymus and the possibility of an endogenous melatonin synthesis in this organ, in which T cells are matured. In this work, we demonstrate in humans and rats that thymus contains melatonin, expresses the mRNAs encoding N-acetyltransferase and hydroxyindol-O-methyltransferase, the two key enzymes of the melatonin synthesis, and has this biosynthetic machinery activated. In addition, rat thymocytes cultured for 24 h exhibited high levels of melatonin. The results presented here suggest that human and rat thymuses are able to synthesize melatonin, which could have intracrine, autocrine and paracrine functions.


Subject(s)
Melatonin/biosynthesis , Thymus Gland/metabolism , Adult , Aged , Animals , Female , Humans , Male , Middle Aged , Models, Biological , Rats , Rats, Wistar
13.
Histol Histopathol ; 20(3): 713-8, 2005 07.
Article in English | MEDLINE | ID: mdl-15944919

ABSTRACT

Thyrotropin-releasing hormone (TRH) synthesized in the hypothalamus has the capability of inducing the release of thyroid-stimulating hormone (TSH) from the anterior pituitary, which in turn stimulates the production of thyroid hormones in the thyroid gland. Immunoreactivity for TRH and TRH-like peptides has been found in some tissues outside the nervous system, including thyroid. It has been demonstrated that thyroid C-cells express authentic TRH, affecting thyroid hormone secretion by follicular cells. Therefore, C-cells could have a paracrine role in thyroid homeostasis. If this hypothesis is true, follicular cells should express TRH receptors (TRH-Rs) for the paracrine modulation carried out by C-cells. In order to elucidate whether or not C-cell TRH production could act over follicular cells modulating thyroid function, we studied TRH-Rs expression in PC C13 follicular cells from rat thyroid, by means of immunofluorescence technique and RT-PCR analysis. We also investigated the possibility that C-cells present TRH-Rs for the autocrine control of its own TRH production. Our results showed consistent expression for both receptors, TRH-R1 and TRH-R2, in 6-23 C-cells, and only for TRH-R2 in PC C13 follicular cells. Our data provide new evidence for a novel intrathyroidal regulatory pathway of thyroid hormone secretion via paracrine/autocrine TRH signaling.


Subject(s)
Receptors, Thyrotropin-Releasing Hormone/genetics , Thyroid Gland/metabolism , Animals , Cell Line , Fluorescent Antibody Technique/methods , Gene Expression , Paracrine Communication/physiology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Receptors, Thyrotropin-Releasing Hormone/analysis , Reverse Transcriptase Polymerase Chain Reaction , Thyroid Gland/cytology
14.
Cell Mol Life Sci ; 60(10): 2272-8, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14618273

ABSTRACT

The neurohormone melatonin plays a fundamental role in neuroimmunomodulation of several mammalian species, including mice. This effect is supported by the existence of specific melatonin-binding sites in murine immunocompetent organs. Moreover, using melatonin receptor analogues, several effects of the neurohormone on mice physiology through its membrane and nuclear receptors have been described. The expression of these receptors has never been studied, despite indirect evidence showing the presence of melatonin receptor in the murine immune system. At present, the MT1 and MT2 membrane receptors, and nuclear receptors belonging to the RZR/ROR family have been related to the immunomodulator effect of melatonin. Here, we show the presence of membrane and nuclear melatonin-binding sites in mouse thymus and spleen, using the specific melatonin membrane (S 20098) and nuclear (CGP 52608) receptor agonist. To confirm the presence of melatonin receptors, we analyzed the presence of membrane and nuclear receptor mRNA and protein by RT-PCR, Southern blot, and Western blot. Thus, we show that MT1 and RORalpha receptor mRNA and protein are expressed in both thymus and spleen, while MT2 receptor mRNA is only detected in the thymus. This expression of melatonin receptors strongly supports the idea of an immunomodulatory role of melatonin through its receptors.


Subject(s)
Cell Membrane/metabolism , Cell Nucleus/metabolism , Receptors, Melatonin/genetics , Spleen/metabolism , Thymus Gland/metabolism , Animals , Binding Sites , Mice , Receptors, Melatonin/biosynthesis
15.
Rev. esp. enferm. metab. óseas (Ed. impr.) ; 12(3): 63-67, mayo 2003. graf, tab
Article in Es | IBECS | ID: ibc-27979

ABSTRACT

El sistema RANK/RANKL/OPG* se ha destacado en los últimos años como un regulador de la actividad osteoclástica. Un desequilibrio en este sistema provoca una alteración del remodelado óseo. En este trabajo hemos estudiado a 80 mujeres adultas y hemos determinado sus niveles séricos de OPG en función de la edad, la existencia o no de osteoporosis por medición de densidad mineral ósea (DMO) en columna lumbar, y la existencia de fracturas de Colles y de cadera. Los niveles de OPG se correlacionaron positivamente con la edad (p < 0,0001), y de forma negativa con la DMO (p = 0,002); se obtuvieron unos menores valores de OPG entre las mujeres postmenopáusicas con osteoporosis sin fracturas de Colles ni de cadera en comparación con las no osteoporóticas, y valores superiores en las mujeres osteoporóticas con fractura de Colles con respecto a las que no tenían fracturas. Consideramos que la mayor producción de OPG observada con la edad pudiera ser un mecanismo protector para compensar la mayor resorción ósea, y posiblemente, cuando aquélla no sea suficiente, se favorezca la aparición de osteoporosis (AU)


Subject(s)
Adult , Aged , Female , Middle Aged , Aged, 80 and over , Humans , Biomarkers/blood , Osteoporosis/blood , Receptors, Cytoplasmic and Nuclear/blood , Bone Density
16.
Life Sci ; 65(20): 2143-50, 1999.
Article in English | MEDLINE | ID: mdl-10579467

ABSTRACT

Melatonin could act on immune system by regulating cytokine production of immunocompetent cells. The hormone enhances IL-2, IFN-gamma and IL-6 production by cultured human mononuclear cells. As enhancement of IL-6 production is related to monocyte activation by melatonin, the hormone acts on human lymphoid cells causing a Th1-type response. This paper shows that melatonin seems to promote a Th1-response by increasing IL-12 production. The hormone enhances IL-12 production by cultured monocytes under suboptimal stimulation in a dose-dependent way. The effect of the hormone increases when PBMCs are incubated with melatonin before monocyte isolation. Enhanced IL-12 production by melatonin can also be shown in cultured human mononuclear cells.


Subject(s)
Interleukin-12/biosynthesis , Lymphocyte Activation/drug effects , Melatonin/pharmacology , Th1 Cells/immunology , Cells, Cultured , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay , Humans , Interferon-gamma/pharmacology , Interleukin-2/biosynthesis , Interleukin-6/biosynthesis , Lipopolysaccharides/pharmacology , Monocytes/drug effects , Monocytes/immunology
17.
J Pineal Res ; 26(4): 227-35, 1999 May.
Article in English | MEDLINE | ID: mdl-10340725

ABSTRACT

Melatonin, the chief secretory product of the pineal gland, is a potent and efficient endogenous radical scavenger. Thus, melatonin was shown to protect different biomolecules, such as DNA, membrane lipids, and cytosolic proteins, from oxidative damage induced by oxygen-derived free radicals. In order to study the protective role of melatonin in hydrogen peroxide (H2O2)-induced DNA damage, U-937 cells were treated with different concentrations of H2O2, either in the presence or absence of melatonin, and DNA damage was assessed using the cytokinesis-block micronucleus technique. Melatonin diminished H2O2-induced micronuclei production both in short and long treatments. Additionally, melatonin concentrations higher than 1 microM were capable of protecting cells from spontaneous micronuclei production. These data suggest that melatonin, an endogenous antioxidant and nontoxic compound, may have an important role in protecting cells from genetic damage due to free radicals, supporting the idea of this hormone as a possible therapeutic agent in preventing aging and age-related diseases.


Subject(s)
DNA Damage/drug effects , Hydrogen Peroxide/antagonists & inhibitors , Melatonin/pharmacology , Antioxidants/pharmacology , Cell Death/drug effects , Cell Nucleus/drug effects , Cell Nucleus/metabolism , Cell Survival/drug effects , Cytochalasin B/pharmacology , Dose-Response Relationship, Drug , Humans , Hydrogen Peroxide/pharmacology , Hydroxyl Radical/antagonists & inhibitors , Hydroxyl Radical/pharmacology , Micronucleus Tests , Oxidants/antagonists & inhibitors , Oxidants/pharmacology , Pineal Gland/metabolism , Time Factors , U937 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...